tert-Butyl 2-(2-methoxyethyl)hydrazinecarboxylate | 1292303-78-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-Butyl 2-(2-methoxyethyl)hydrazinecarboxylate
• 英文别名: tert-butyl N-(2-methoxyethylamino)carbamate
• CAS: 1292303-78-6
• 化学式: C₈H₁₈N₂O₃
• 分子量: 190.243
• InChiKey: IPFYZEJBPAOSEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  59.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-Butyl 2-(2-methoxyethyl)hydrazinecarboxylate 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 tert-butyl (4R,5S)-4-amino-5-(3,4-difluorophenyl)-2-(2-methoxyethyl)pyrazolidine-1-carboxylate
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY

  摘要：

  公开号：

  EP3330256B1
• 作为产物：
  描述：

  肼基甲酸叔丁酯 、 2-溴乙基甲基醚 在 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 二甲基亚砜 为溶剂， 反应 20.0h， 以12%的产率得到tert-Butyl 2-(2-methoxyethyl)hydrazinecarboxylate
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY

  摘要：

  公开号：

  EP3330256B1

文献信息

• Compounds and Methods for Producing a Conjugate
  申请人：Redwood Bioscience, Inc.

  公开号：US20160038602A1

  公开（公告）日：2016-02-11

  The present disclosure provides conjugate structures and compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

  本公开提供用于生产这些共轭物结构和化合物结构的共轭结构和化合物结构。本公开还涵盖了生产这种共轭物的方法，以及使用它们的方法。
• Heterocycle derivatives having TrkA inhibitory activity
  申请人：Shionogi & Co., Ltd.

  公开号：US10640495B2

  公开（公告）日：2020-05-05

  The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein -L- is —C(═X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a single bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, and the group represented by is a group represented by Formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.

  本发明提供了一种具有 TrkA 抑制活性的化合物或其药学上可接受的盐。 本发明涉及一种由式（I）表示的化合物： 其中-L-是-C(═X)-，或类似物，-Z-是-NR5-，或类似物，-ZA-是-NR5A-，或类似物，B是取代或未取代的芳香族碳环，或类似物，Y是单键，或类似物，环C是取代或未取代的芳香族杂环，或类似物，R2是氢原子，或类似物，以及由以下式子代表的基团 是一个由公式表示的组： 或其药学上可接受的盐，以及由其组成的药物组合物。
• Novel dihydrothieno[2,3-e]indazole derivatives as IκB kinase inhibitors
  作者：Hiroyasu Takahashi、Mariko Shinoyama、Takashi Komine、Muneki Nagao、Masashi Suzuki、Hisatoshi Tsuchida、Koichi Katsuyama

  DOI：10.1016/j.bmcl.2011.01.069

  日期：2011.3

  Synthesis, and structure-activity relationship (SAR) studies of the novel IKK-beta inhibitors 2 and 3 characterized by a dihydrothieno[2,3-e]indazole core are presented. Compound 2t was efficacious in a mouse model of LPS-stimulated TNF-alpha production. (C) 2011 Elsevier Ltd. All rights reserved.
• HETEROCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：US20180201607A1

  公开（公告）日：2018-07-19

  The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein -L- is —C(═X)—, or the like, —Z— is —NR 5 —, or the like, —Z A — is —NR 5A —, or the like, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a single bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R 2 is a hydrogen atom, or the like, and the group represented by is a group represented by Formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.
• CN115572249
  申请人：——

  公开号：——

  公开（公告）日：——